SCHEMBL4866797

SCHEMBL4866797

Cc1oc2nc(N(C)C)nc(NCc3ccccn3)c2c1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.52
KCNA5 P22460 6/20 0.44
MAPK14 Q16539 3/20 0.40
MAPK13 O15264 2/20 0.40
MAPK12 P53778 2/20 0.40
MAPK11 Q15759 2/20 0.40
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
HIF1A Q16665 1/20 0.38
PDE5A O76074 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
JAK2 O60674 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870568 0.83 KCNA5 (0.43) KCNH2KCNA5MAPK14MAPK13MAPK12
SCHEMBL4868763 0.77 KCNA5 (0.49) KCNH2KCNA5HIF1APDE5ALMNA
SCHEMBL3384953 0.76 KCNH2 (0.57) KCNH2KCNA5LMNAJAK2KDM4E
SCHEMBL5246200 0.74 KCNH2 (0.46) KCNH2KCNA5HIF1APDE5ALMNA
SCHEMBL4871028 0.74 AURKA (0.61) KCNH2KCNA5MAOAMAOBLMNA
SCHEMBL4867940 0.70 KCNA5 (0.47) KCNH2KCNA5MAPK14MAPK13MAPK12
SCHEMBL2368637 0.70 KCNA5 (0.43) KCNH2KCNA5MAPK14MAPK13MAPK12
SCHEMBL2369089 0.67 KCNH2 (0.67) KCNH2KCNA5LMNAJAK2ALDH1A1
SCHEMBL3386735 0.66 TNF (0.59) KCNH2KCNA5LMNATSHRHTT
SCHEMBL2369248 0.66 KCNA5 (0.45) KCNH2KCNA5MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 KCNH2 3/4885KCNA5 6/4885MAPK14 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.